Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Kaleida Capital is a venture capital firm founded by Dr. Ariane Tom. Established in the United States, the firm focuses on neurotechnology and artificial intelligence. The organization aims to support the development of brain-inspired technologies that enhance human abilities and enable precision medicine. Dr. Tom's vision drives the firm to invest in transformative technologies that can significantly impact healthcare and human performance.
The firm actively engages in the early-stage investment landscape, targeting pre-seed, seed, seed-plus, and Series A funding rounds. Kaleida Capital has built a portfolio that reflects its commitment to advancing innovative solutions in neurotechnology and AI. The firm operates from its headquarters in the United States and has established a reputation for its focus on breakthrough technologies.
As of now, Kaleida Capital continues to expand its portfolio and influence in the neurotechnology and AI sectors. The firm has made notable strides in curating a diverse range of investments that align with its mission of enhancing human capabilities through technology.
Kaleida Capital invests primarily in the neurotechnology and artificial intelligence sectors. The firm emphasizes areas such as neural data infrastructure, human performance, and digital interfaces. Their investment strategy is centered on identifying early-stage companies that are developing breakthrough technologies in neural engineering, brain-computer interfaces, and deep AI applications.
The firm seeks to partner with startups that demonstrate innovative approaches to enhancing human abilities and improving healthcare outcomes. Kaleida Capital's focus on precision medicine and brain-inspired technologies positions it uniquely within the venture capital landscape. The organization is particularly interested in companies that can leverage AI to create impactful solutions in mental health and neurological disorders.
Kaleida Capital's portfolio features a range of innovative companies making significant strides in neurotechnology and AI. Notable investments include:
This diverse portfolio reflects Kaleida Capital's commitment to supporting groundbreaking technologies that enhance human capabilities and address critical healthcare challenges.
Dr. Ariane Tom - Founder & Managing Director. Dr. Tom has a background in neuroscience and has led numerous investments in neurotechnology and AI.
Dr. Kevin Carlberg - Venture Partner. Dr. Carlberg brings expertise in biomedical engineering and has a track record of successful investments in healthcare technology.
Dr. Srihari Sritharan - Venture Fellow. Dr. Sritharan specializes in AI applications in healthcare and supports portfolio companies in technology development.
Dr. Sharena Rice - Venture Fellow. Dr. Rice focuses on human performance technologies and assists in evaluating potential investments.
Chad Sadili - Operations Associate and Executive Assistant. Chad supports the operational aspects of the firm and helps manage portfolio company relations.
To pitch to Kaleida Capital, founders should visit their website at kaleidacapital.com. The firm prefers detailed pitch decks that outline the technology, market opportunity, and team qualifications. Founders should expect a response within a few weeks after submission.
Warm introductions are beneficial but not mandatory. Clear communication of the startup's vision and alignment with Kaleida Capital's focus areas will enhance the chances of a successful pitch.
In recent months, Kaleida Capital has made significant investments in innovative companies within the neurotechnology and AI sectors. Highlights include a computational neuroimaging platform aimed at improving drug development for mental health conditions and a brain-computer interface technology designed to restore motor functions in patients with severe disabilities.
The firm continues to curate a portfolio that reflects its commitment to advancing technologies that enhance human capabilities. As of now, no public blog activity has been detected, but the firm remains active in the investment community.
What are Kaleida Capital's investment criteria?
Kaleida Capital focuses on early-stage companies in the neurotechnology and AI sectors. They look for startups developing breakthrough technologies in neural engineering, brain-computer interfaces, and deep AI applications.
How can I apply or pitch to Kaleida Capital?
Founders can submit their pitches through the Kaleida Capital website at kaleidacapital.com. It is advisable to include a detailed overview of the technology and its potential impact.
What makes Kaleida Capital different from other venture firms?
Kaleida Capital specializes in neurotechnology and AI, focusing on enhancing human capabilities through brain-inspired technologies. Their unique investment thesis emphasizes precision medicine and human performance.
What is the geographic scope of Kaleida Capital's investments?
The firm primarily invests in companies based in the United States, targeting early-stage ventures that align with their focus areas.
What is the typical check size for investments?
Kaleida Capital invests at various early stages, including pre-seed, seed, seed-plus, and Series A, with check sizes varying based on the stage and potential of the startup.
What kind of post-investment involvement does Kaleida Capital have?
Kaleida Capital actively engages with its portfolio companies, providing support and resources to help them scale and succeed in their respective markets.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.